Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome
Condition(s):Wiskott-Aldrich SyndromeLast Updated:May 6, 2020Unknown status
Hide Studies Not Open or Pending
Condition(s):Wiskott-Aldrich SyndromeLast Updated:May 6, 2020Unknown status
Condition(s):Lymphoma Patients; ThrombocytopeniaLast Updated:August 22, 2023Active, not recruiting
Condition(s):Immune ThrombocytopeniaLast Updated:January 14, 2015Unknown status
Condition(s):Hematologic MalignanciesLast Updated:June 8, 2021Completed
Condition(s):Immune ThrombocytopeniaLast Updated:June 23, 2022Completed
Condition(s):Multiple Myeloma; Hodgkin Lymphoma; Non-Hodgkin Lymphoma; HDT-AHCTLast Updated:February 14, 2024Completed
Condition(s):Non Severe Aplastic AnemiaLast Updated:August 24, 2023Not yet recruiting
Condition(s):Wiskott-Aldrich SyndromeLast Updated:December 28, 2020Completed
Condition(s):Chemotherapy-induced ThrombocytopeniaLast Updated:March 7, 2024Recruiting
Condition(s):Immune ThrombocytopeniaLast Updated:May 7, 2020Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.